A 28-year-old woman at 16 weeks gestation is in medication-assisted treatment with buprenorphine 16 mg daily for opioid use disorder. She is stable and has not used illicit opioids in 8 months. She asks the PMHNP whether she should taper off buprenorphine during pregnancy to prevent neonatal abstinence syndrome (NAS). The PMHNP must counsel her on the evidence.